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OBJECTIVES The goal of this study was to investigate possible differences in thrombin generation or
fibrinolytic capacity in patients with unstable angina (UA) or acute myocardial infarction
(AMI) with or without recurrent angina at rest.
BACKGROUND Angina at rest in patients with AMI or UA is generally produced by a reduction in coronary
flow, but it is unclear whether patients with or without this event differ in their thrombin
generation or in their fibrinolytic capacities, which might influence the course of the culprit
lesion.
METHODS Thrombin-antithrombin complex (TAT), D-dimer, fibrinogen and plasminogen activator
inhibitor (PAI-1) antigen plasma levels were determined in 40 patients with AMI and in 23
with UA on admission, at 10 days and at three months.
RESULTS First day values for TAT, fibrinogen and D-dimer were comparable in patients with AMI and
in those with UA. At 10 days they increased significantly in each group, and at 3 months they
decreased to a similar extent. First day PAI-1 levels, however, were highest in both groups
and declined in AMI patients at 10 days and at three months, whereas they also decreased at
10 days in UA patients but not any further at three months. Ten patients with AMI (25%)
and 12 with UA (52%) developed in-hospital angina at rest. First day values for TAT,
fibrinogen and D-dimer were similar in patients with or without angina, but PAI-1 levels
were higher in the former subset (p , 0.008). At 10 days, however, TAT (p , 0.013) and
D-dimer (p , 0.013) were higher in patients who developed angina than in those who did
not.
CONCLUSIONS The higher inhibition of fibrinolytic activity in the first day in patients with AMI or UA who
will develop recurrent angina suggests that maintenance of a prothrombotic status may
contribute to its mechanisms, perhaps by preventing passivation of the culprit thrombus/
plaque. This is consistent with greater thrombin generation and greater levels of fibrynolitic
products at 10 days observed in these patients compared with those who attain early stability.
(J Am Coll Cardiol 2000;36:2036–43) © 2000 by the American College of Cardiology
Angina at rest while in the hospital is a complicating event
in patients with either unstable angina (UA) or acute
myocardial infarction (AMI). Advanced coronary artery
disease (1–4) and a reduced coronary reserve are associated
with an increased incidence of recurrent episodes that are
mostly related to transient decreases in coronary flow (5,6).
They appear to be favored by temporal decreases in ischemic
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threshold that have been attributed to increases in coronary
tone, which tend to follow a circadian pattern (7,8). It is
unclear, however, whether abnormalities in the fibrinolytic
activity or in the formation of thrombin may also contribute
to the persistence of an unstable condition allowing the
persistence of an active thrombus overlying the complicated
plaque or fissure (9). In addition, it is also unknown whether
these hypothetical abnormalities are similarly present in
patients with UA and in those with AMI and whether they
persist during hospitalization or in the early follow-up.
Since plasminogen activator inhibitor, type 1 (PAI-1) and
tissue plasminogen activator act in concert to regulate
plasminogen conversion to plasmin, their levels are indirect
markers of the fibrinolytic activation (10). Indeed, a de-
creased fibrinolytic activity demonstrated by a prolonged
lysis time is accompanied by elevated PAI-1 antigen levels
(11,12), and plasmin formation is strongly dependent on
PAI-1 levels (12). On the other hand, fibrin D-dimer
indicates intravascular turnover of fibrin by identifying a
primary degradation product of cross-linked fibrin. Thus, it
is a direct marker of endogenous fibrinolysis (10), and it is
found in conditions associated with intravascular activation
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of the coagulation process (13). Moreover, thrombin-
antithrombin complex (TAT) is a reliable indicator of
ongoing thrombin formation. Thus, the aims of this study
were to analyze in patients with a first episode of UA or a
first episode of AMI the possible changes in plasma levels of
fibrinogen, TAT, d-dimer and PAI-1 during hospitaliza-
tion and at 3 months of follow-up and to assess the possible
differences between those who develop recurrent angina at
rest and those who do not.
METHODS
Patients. The study population consisted of 77 patients
admitted to our coronary care unit, 48 with AMI and 29
with UA. The clinical diagnosis of AMI was based on the
concurrence of chest pain, elevated myocardial enzymes
(total and MB creatine kinase above twice the upper normal
limit) and electrographic changes (ST segment elevation or
depression). Diagnosis of UA included the presence of
typical angina at rest associated with acute and transient ST
segment or T wave changes, with or without progressive
exercise-induced angina without enzyme elevation. Exclu-
sion criteria were: age .75 years, presence of Killip class III
or IV, left bundle branch block, associated cardiac diseases,
previous myocardial infarction, hospital admission for UA,
coronary artery bypass grafting or coronary angioplasty.
Twenty-six nonsmokers and healthy individuals, age 47 6 5
years, constituted the control group.
Study protocol. Patients were treated with intravenous
heparin to maintain a partial thromboplastine time approx-
imately twice the control value during the first 2 to 6 days
and with aspirin, 250 mg orally. Those with UA and those
with AMI who presented recurrent angina also received
intravenous nitroglycerin and beta-adrenergic blocking
agents. In patients with AMI beta-blockers were initiated
during the first five days. Calcium antagonists were added if
recurrent angina persisted. During the follow-up patients
from both groups received aspirin 250 mg daily and most
also received beta-blockers. Those with occasional angina
also received nitrates or calcium antagonists. The protocol
was approved by the Hospital ethics committee, and in-
formed consent was obtained before entering the study.
Blood sampling. All patients underwent venous blood
sampling on the first 24 h after initiation of intravenous
heparin and also on days 10 through 12 and at three months
of follow-up. In patients who received thrombolytic ther-
apy, the first sample was drawn before its administration.
Samples were drawn between 8:30 and 9:30 AM in a fasting
condition without vascular compression and with the pa-
tient lying in bed for at least the preceding 30 to 45 min.
The first 3 ml of blood were discarded; then, 4.5 ml of blood
and 0.5 ml of sodium citrate (0.13 M) for TAT, D-dimer
and fibrinogen measurements were mixed, and 5 ml of
blood were placed in a diatube for PAI-1 measurements.
Samples were then centrifuged at 2,000 g for 20 min at 4°C,
and the citrated tube was stored at 280°C until analyzed.
Laboratory methods. Enzyme-linked immunosorbent as-
says were used to determine plasma concentrations of PAI
antigen (Tintelize PAI-1, Biopool, Sweden), TAT (Enzys-
nost TAT Micro, Behring, Marbourg, Germany) and
D-dimer (Fibrinostika FbDP, Organon Teknika, Boxtel,
the Netherlands). Fibrinogen plasma levels were measured
by the Von Clauss coagulative method. The lower limits of
detection and the co-efficient of variation for PAI-I antigen
were 0.5 ng/ml and 6%; for TAT they were 0.5 mg/l and
8.9%; for D-dimer they were 11 ng/ml and 14%, and for
fibrinogen they were 0.2 g/l and 4.8%, respectively.
Coronary angiography. Of the initial 77 patients, 14 were
excluded because of lack of some blood samples (n 5 4),
inadequate sampling technique (n 5 3) or need for couma-
din therapy (n 5 2) or coronary surgery (n 5 5). Thus, a
total of 63 patients, 23 with UA and 40 with AMI, were
finally included. A coronary angiography was performed
during hospitalization in 51, in 38 within the first 10 days
and in 13 beyond day 10, and a contrast left ventriculogram
was performed in 47. Technical restrains, or patient refusal
prevented performance of cardiac catheterization in 12. A
.70% stenosis of a major coronary vessel was considered
significant.
Statistical analysis. The chi-square test or the Fisher exact
test was used to compare categoric variables. The intragroup
and intergroup (interaction term) differences for continuous
variables were assessed using analysis of two-way repeated
measures, analysis of variance. The student t test for
unpaired samples was used for intergroup differences be-
tween one time measurements. The data are expressed as
mean 6 standard deviation.
RESULTS
Clinical and angiographic data. Table 1 summarizes most
relevant information. Fifteen patients with AMI received
thrombolytic therapy, and 22 (34.9%), 10 with AMI and 12
with UA, developed angina at rest while in the hospital
(1.9 6 2.3 episodes for UA and 0.5 6 0.9 for AMI).
Patients with in-hospital angina were comparable to those
without except for a lower incidence of smoking and a
higher incidence of antecedent angina (.1 month). They
also had a higher ejection fraction, in part accounted for by
the lower proportion of patients with AMI (10/22, 45% vs.
30/41, 73%). The MB creatine kinase for AMI patients was
200 6 129 IU/l (upper normal level, 25 IU/l). All 63
patients received intravenous heparin, mostly during the
first two to four days and oral aspirin. Also, 45 (71.4%)
received beta-blockers, 34 (54%) intravenous nitroglycerin,
Abbreviations and Acronyms
AMI 5 acute myocardial infarction
PAI-1 5 plasminogen activator inhibitor, type 1
TAT 5 thrombin-antithrombin complex
UA 5 unstable angina
2037JACC Vol. 36, No. 7, 2000 Figueras et al.
December 2000:2036–43 Angina at Rest and Fibrinolytic Activity
32 (50.8%) oral or topical nitrates and 20 (31.7%) calcium
antagonists. Sixteen patients, 5 with AMI and 11 with UA,
underwent a coronary angioplasty, 11 within the first 7 days
(day 3.3 6 1.7) and 5 between day 10 and 20. Only two
patients received a stent implantation. None of the patients
died while in the hospital, but one from the group of
patients with AMI had a reinfarction and another from the
group of patients with UA had an AMI at one month of
follow-up.
Fibrinogen, TAT, PAI-1 (antigen) and D-dimer mea-
surements. Median time from onset of pain to the first
blood sampling was 7:20 h (1:15 to 18:10 h) in patients with
UA and 6:17 (1:22 to 17:30 h) in those with AMI. In both
groups fibrinogen levels were highest at 10 days and
Table 1. Clinical and Angiographic Data: Comparison of Patients With and Without
In-hospital Angina
All
(n 5 63)
In-H Angina
(n 5 22)
No Angina
(n 5 41)
p
Value*
Age (yr) 57.8 6 10.9 61.0 6 9.7 56.4 6 11.2 NS
Male gender 52 (82.5%) 17 (77.3%) 35 (85.4%) NS
Systemic hypertension 25 (40%) 9 (40.9%) 16 (39%) NS
Diabetes mellitus 11 (17.5%) 4 (18.2%) 7 (17%) NS
Cholesterol (mg/dl) 202 6 43 216 6 44 194 6 41 NS
Triglycerides (mg/dl) 149 6 64 169 6 54 136 6 66 , 0.05
Smoking 39 (61.9%) 10 (45.5%) 29 (70.7%) , 0.05
Angina .1 month 22 (34.9%) 13 (50.1%) 9 (22%) , 0.01
Coronary stenosis (.70%) (n 5 51) (n 5 22) (n 5 29)
0 vessels 2 (3.9%) 1 (4.5%) 1 (3.4%) NS
1 vessel 22 (43.1%) 7 (31.8%) 15 (51.7%) NS
2 vessels 19 (37.3%) 11 (50%) 8 (27.6%) NS
3 vessels 6 left main 8 (15.7%) 3 (13.6%) 5 (17.2%) NS
LVEF (%) (n 5 43) (n 5 18) (n 5 25)
62.1 6 13.0 67.4 6 9.8 57.3 6 13.3 , 0.02
*Differences between patients with in-H angina and no angina.
In-H 5 in-hospital; LVEF 5 left ventricular ejection fraction.
Table 2. In-hospital (Days 1 and 10) and Follow-up Values (Three Months) for Plasma TAT,
PAI-1, Fibrinogen and D-dimer of Patients With Acute Myocardial Infarction
All
(n 5 40)
In-H Angina
(n 5 10)
No Angina
(n 5 30)
p
Value*
Fibrinogen (g/l)
Day 1 4.2 6 1.5 3.5 6 0.8 4.5 6 1.6 , 0.02
Day 10 4.9 6 1.4 4.8 6 0.9 5.0 6 1.5 NS
3 months 3.4 6 0.8 3.5 6 0.7 3.4 6 0.9 NS
p value† , 0.0005 , 0.001 , 0.0005
p value‡ , 0.11
TAT (mg/l)
Day 1 5.8 6 2.3 5.2 6 1.5 5.9 6 2.5 NS
Day 10 7.1 6 3.1 8.3 6 3.3 6.7 6 3.0 NS
3 months 5.2 6 2.4 4.9 6 2.7 5.3 6 2.3 NS
p value† , 0.0005 , 0.014 , 0.04
p value‡ , 0.10
PAI-1 (ng/ml)
Day 1 56.5 6 20.5 68.5 6 22.8 52.4 6 18.3 , 0.03
Day 10 45.3 6 14.3 49.7 6 8.7 43.8 6 15.6 NS
3 months 37.7 6 17.7 37.0 6 14.7 38.0 6 18.8 NS
p value† , 0.0001 , 0.0001 , 0.001
p value‡ , 0.06
D-dimer (ng/ml)
Day 1 482 6 580 502 6 304 476 6 651 NS
Day 10 958 6 640 1311 6 885 840 6 500 , 0.14
3 months 394 6 198 473 6 291 367 6 154 NS
p value† , 0.0005 , 0.004 , 0.001
p value‡ , 0.19
*differences between in-hospital angina and no angina; †intragroup comparison (analysis of variance); ‡intergroup comparison
(interaction term, analysis of variance).
In-H 5 in-hospital; PAI-1 5 plasminogen activator inhibitor; TAT 5 thrombin-antithrombin complex.
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declined significantly in the follow-up (Tables 2 and 3). At
the three stages values were similar in the two groups and
were significantly higher than they were in the control group
(2.9 6 0.4 g/l, p , 0.005). Patients with in-hospital angina
showed similar values than those who remained asymptom-
atic, either when considering all patients (Fig. 1) or only
those with AMI or UA (Table 3). Although first day values
were higher in asymptomatic patients with AMI, intergroup
analysis showed no significant differences (Fig. 1, Tables 2
and 3).
Thrombin-antithrombin complex values were highest at
10 days in AMI patients, and they showed a similar trend in
those with UA (Tables 2 and 3). Values at the three stages
were comparable in the two groups and were significantly
higher than they were in the control group (3.4 6 1.4 mg/l,
p , 0.005). For all 63 patients values at 10 days were higher
in those with in-hospital angina than they were in those
without (p , 0.013, Fig. 1). Among patients with UA those
who remained unstable while in the hospital had higher
values at 3 months than those who remained asymptomatic
(Tables 2 and 3). Intergroup analysis showed no significant
differences except for a trend towards significance in the
overall comparison between patients with or without in-
hospital angina (p , 0.077, Fig. 1).
In patients with AMI measurements of PAI-1 were
highest on the first day, and a similar trend was observed in
those with UA. First day and 10 day levels were comparable
in the two subsets (Tables 2 and 3). For all 63 patients (Fig.
2), as well as for each of the two subsets (Tables 2 and 3),
those with in-hospital angina had higher first day values
than those who remained asymptomatic. Intergroup analysis
revealed a significant difference for the overall group (p ,
0.029, Fig. 2). Also, first day values of PAI-1 were
.50 ng/ml in 16 of 22 patients with in-hospital angina
(72.7%) and in 14 of 41 without (34.1%, p , 0.01) and were
significantly higher than those in the control group (27.3 6
24.2, p , 0.001).
In patients with AMI or UA first day values for D-dimer
(Tables 2 and 3) were higher than they were in the control
group (273 6 78 ng/ml, p , 0.02 and p , 0.01, respec-
tively). At 10 days they increased significantly, and at each
of the three stages values were comparable in the two
subsets (Tables 2 and 3). When considering all patients,
those with recurrent angina had a greater increase in
D-dimer at 10 days than those without (p , 0.004, Fig. 2).
A similar trend occurred in the two groups although in the
UA group the difference was of borderline significance
(Tables 2 and 3). Intergroup analysis showed significant
differences for the overall group (p , 0.029, Fig. 2) and for
the group with UA (Table 3). Values .600 ng/ml were
present in 18 of 22 patients with in-hospital angina (81.8%)
and in 24 of 41 of those who remained asymptomatic
(58.5%, p , 0.054).
In 54 of 63 patients (83.7%) the 10th day sample was
taken either before coronary angiography or 4 days after the
procedure, whereas in the remaining nine sampling was
Table 3. In-hospital (Days 1 and 10) and Follow-up Values (3 Months) for Plasma TAT, PAI-
1, Fibrinogen and D-dimer of Patients With Unstable Angina
All
(n 5 23)
In-H Angina
(n 5 12)
No Angina
(n 5 11)
p
Value*
Fibrinogen (g/l)
Day 1 4.0 6 1.0 3.9 6 1.2 4.0 6 0.9 NS
Day 10 4.7 6 0.9 4.8 6 1.0 4.6 6 0.7 NS
3 months 3.9 6 108 3.9 6 1.2 3.9 6 0.9 NS
p value† , 0.012 NS , 0.07
p value‡ NS
TAT (mg/l)
Day 1 6.3 6 3.7 6.7 6 4.0 5.9 6 3.5 NS
Day 10 7.6 6 3.9 9.0 6 4.5 6.1 6 2.4 , 0.075
3 months 5.2 6 2.2 6.1 6 2.6 4.2 6 0.9 , 0.04
p value† , 0.026 NS NS
p value‡ NS
PAI-1 (ng/ml)
Day 1 53.6 6 19.2 60.9 6 20.3 45.6 6 14.9 , 0.06
Day 10 43.9 6 12.6 44.2 6 13.4 43.6 6 12.4 NS
3 months 49.2 6 16.7 45.7 6 13.6 53.1 6 19.5 NS
p value† , 0.083 , 0.02 NS
p value‡ , 0.27
D-dimer (ng/ml)
Day 1 367 6 140 378 6 126 356 6 159 NS
Day 10 831 6 633 1,069 6 781 570 6 259 , 0.05
3 months 390 6 194 379 6 184 401 6 214 NS
p value† , 0.0005 , 0.002 , 0.02
p value‡ 0.038
Abbreviations as in Table 2.
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performed 24 to 72 h after the procedure. Thus, in the 38
patients who underwent catheterization within the first 10
days, the interval between catheterization and the 10th day
sampling was 5.0 6 2.3 days. Moreover, at 10 days patients
were no longer receiving heparin, which had been discon-
tinued within the first four to five days in most of them.
DISCUSSION
Fibrinogen and TAT measurements. Consistent with
previous observations (14–16) patients with AMI or UA
had higher fibrinogen levels on the first day than did a
control population. In addition we noted a further increase
at 10 days similar to that reported by Aznar et al. (17), and
that might be attributable to an acute phase reaction
(18–20). More specifically, however, we demonstrated that
these values were comparable in the two subsets. We also
observed that TAT levels increased during hospitalization
to a similar extent in the two groups. The results in patients
with UA are in line with those reported by Hoffmeister et al.
(21), Al-Nozha et al. (22) and Biasucci et al. (23), who also
found increases in TAT levels during hospitalization. These
investigators (21–23), however, limited their measurements
to the first days, had no early follow-up data and did not
compare the results of UA patients with the results of
patients with AMI (22,23). In our study the increases in
thrombin generation at 10 days corresponding to the in-
creases in TAT declined at three months but remained
higher than they did in control subjects. Similarly, Merlini
et al. (24) documented that patients with UA or AMI had
a persistent hypercoagulable state at six months of follow-
up.
Figure 1. Thrombin-antithrombin complex (upper panel) and fibrinogen
plasma levels (lower panel) (mean 6 SEM) on days 1 and 10 and at 3
months in patients with unstable angina or acute myocardial infarction
with (dashed bars) or without in-hospital angina (open bars). Also shown
are values from a control group. Thrombin-antithrombin complex values at
the three stages were higher in patients than they were in the control group
(see text). There were significant (*) intragroup differences (ANOVA) in
the two subsets as well as a trend towards intergroup differences (ANOVA,
p , 0.077), mainly because of the higher values at 10 days in patients with
in-hospital angina than in those without (p , 0.013). Fibrinogen levels
were also higher in patients than they were in the control group and
increased significantly at 10 days to a comparable extent in patients with or
without in-hospital angina. Intragroup differences (ANOVA) were signif-
icant (*). ANOVA 5 analysis of variance.
Figure 2. D-dimer (upper panel) and PAI-1 plasma levels (lower panel)
(mean 6 SEM) on days 1 and 10 and at 3 months in patients with unstable
angina or acute myocardial infarction with (dashed bars) or without
in-hospital angina (open bars) and in those from a control group. D-dimer
values at the three stages were higher in patients than they were in the
control group (see text). There were significant intragroup differences (*)
(ANOVA) in the two subsets as well as intergroup differences (ANOVA,
p , 0.029). At 10 days values were significantly higher in patients with
in-hospital angina than they were in those without (p , 0.004). Plasmin-
ogen activator inhibitor, type 1 levels were also higher in patients than they
were in the control group, and there were significant (*) intragroup
(ANOVA) as well as intergroup differences (ANOVA, p , 0.029). The
latter were mainly related to the particularly higher PAI-1 levels on day one
in patients who developed in-hospital angina than in those who did not
(p , 0.008). ANOVA 5 analysis of variance; PAI-1 5 plasminogen
activator inhibitor, type 1.
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PAI-1 and D-dimer measurements. Another observation
of interest was the higher PAI-1 levels found on day one
than at 10 days or at the three months of follow-up. Even
though this was more apparent in patients with AMI, those
with UA also had higher first day than 10 day values,
indicating that both groups had a reduced PAI-1 related
fibrinolytic activity during at least the first 24 h. In patients
with UA, Hoffmeister et al. (21) also found increased levels
of PAI-1 but did not document a decline at 10 days and
Al-Nozha et al. (22) also observed increased levels during
the first five days but did not examine possible changes later
on. Moreover, these authors did not investigate possible
differences between patients with or without recurrent
angina (21,22). In contrast with these studies Alexopoulos
et al. (25) found no change in PAI-1 levels within first 24 h
to 48 h in similar patients. In patients with AMI Sakamoto
et al. (26) observed, as in our study, a transiently reduced
fibrinolytic capacity that became normal a few weeks after
discharge, but the study did not assess possible changes
during the hospital course or differences between patients
with or without recurrent angina.
Also worthwhile was the significant in-hospital increase
in plasma D-dimer levels in patients with AMI or UA.
Similar increases had been previously reported by some
investigators in patients with AMI (27,28) or UA (21,28)
but not by others (25,29). Although Kruskhal et al. (28)
performed only a single measurement and within 1 h of
chest pain in patients with UA or AMI, they showed similar
levels of D-dimer as our first day values (28). Moreover, we
observed a further increase at 10 days that was not docu-
mented by Hoffmeister et al. (21). Among patients with
AMI, increases in D-dimer are known to occur (28,29) and
appear to be particularly elevated in those with heart failure
or ventricular arrhythmias (30). Of interest is that Takano et
al. (31) observed that, in patients with atherothrombotic
strokes, D-dimer values were significantly higher at seven
days than on day one, as in our patients with AMI or UA.
Influence of clinical instability. Previous investigations
that have analyzed TAT (21–23), PAI-1 (21,22) or
D-dimer levels (21) in patients with UA have not evaluated
possible differences between those with or without recurrent
in-hospital angina. This is relevant because our patients who
experienced episodes of angina at rest despite full medical
therapy differed in these parameters from those who re-
mained stable. Thus, even though both subsets, stable and
unstable, presented an increased rate of thrombin formation
at 10 days as indicated by the higher levels of TAT and
D-dimer, which are probably associated with increases in
other markers of acute phase reactants such as fibrinogen—
seen in this study and by others (17)—C-reactive protein
(32–34) or von Willebrand factor (34,35), the change was
more remarkable in the unstable group. This group also had
higher levels of PAI-1 on the first day than those who
remained asymptomatic, and they had a greater fall on day
10. The difference between these findings and those of
Hoffmeister et al. (21) who failed to find a decline of PAI-1
at 10 days may possibly lie in the differences in the clinical
course because they excluded patients with recurrent angina.
At variance with these studies, however, Alexopoulos et al.
(25) found no change in PAI-1 levels within first 24 h to
48 h and failed also to find differences between patients with
or without recurrent angina. Although it is unclear why our
results differ from theirs, for one thing the population and
study design were different (25). In fact, their patients were
older, had more women, some had had previous coronary
events, and the analysis of the recurrence of angina was
limited to the first 48 h (25). Moreover, PAI-1 antigen was
measured by a different technique, samples were not sys-
tematically obtained at the same hour and, as opposed to
previous observations (36), they encountered no circadian
differences in PAI-1 levels. As indicated, failure to note
further increases in D-dimer at 10 days by Hoffmeister et al.
(21) could presumably be attributed to the exclusion of
patients with recurrent angina. Thus, their results in stable
“unstable” patients would be in agreement with those of our
stabilized patients who showed lower values of D-dimer at
10 days than those who remained unstable.
Hypothetically, the increased in-hospital thrombin gen-
eration and D-dimer levels seen in patients with recurrent
angina could possibly be linked, in part, to coincidental
episodes of silent ischemia, like the changes in TAT levels
documented by Biassucci et al. (37). However, at 10 days
the majority of our patients with recurrent angina had
already attained a stable course. Therefore, in view of the
consistent increases in TAT and D-dimer levels at 10 days
on one hand and of their short plasma half-life (5 min for
TAT [38] and 4 to 8 h for D-dimer [28,39]) on the other,
we are more inclined to interpret these changes as originat-
ing from a steady source, such as the inflammatory reaction
that accompanies this unstable condition (16,40,41) than to
an unpredictable source such as asymptomatic episodes of
ischemia.
Another reliable marker of thrombin activity in plasma,
the fibrinopeptide A, has also been shown to increase in
patients with UA who experience in-hospital angina asso-
ciated with ST segment changes (29) or intracoronary
thrombus (42). Moreover, increased fibrinopeptide A levels
have been documented in patients with UA who developed
an AMI during the hospitalization (43).
It is unclear why our patients with AMI and recurrent
angina had a lower initial fibrinolytic activity than those
who remained stable since, apparently, the former subset
would tend to have a less occlusive thrombus. Thus, it is
conceivable that the observed systemic alterations in throm-
bin formation and in fybrinolitic status would be indepen-
dent of the characteristics of the thrombus of the culprit
artery and might be secondary to a more generalized
response, such as the alluded systemic inflammatory reac-
tion. Accordingly, it is possible that unstable patients after
an AMI would present a greater inflammatory response
than the stable ones, as in patients with UA who remain
symptomatic (33). Moreover, our patients with AMI and
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recurrent angina had a larger incidence of preinfarction
angina than those without angina, which is in agreement
with previous reports (3,44). In this regard, it is of interest
that tissue factor plasma levels, which are a primary initiator
of the extrinsic coagulation cascade, have been shown to be
higher in patients with AMI who experienced UA previ-
ously as compared with those who did not (45).
Study limitations. The use of heparin during first day
samples may be considered as a limitation to assess coagu-
lation alterations. However, we deemed it of interest since it
is a widely used treatment, and, hence, the potential
prognostic implications derived from these initial findings
could be applicable to patients with standard therapy. In
previous studies, Hoffmeister et al. (21) and Al-Nozah et al.
(22) also included patients treated with heparin and as-
sumed, as we did, that TAT levels could have been
somewhat higher without this antithrombin therapy. This
effect, however, would be similar in all our subsets of
patients. In addition, and while heparin reduces thrombin
formation and fibrinopeptide A levels—which is a specific
product of fibrinogen cleavage by thrombin—its effects on
D-dimer levels seem to be negligible (27). On the other
hand, 10 day TAT values could have been influenced by
heparin discontinuation for this is a condition associated
with a rapid increase in fibrinopeptide A (46) and thrombin
generation. However, this is a short duration phenomenon
with a return to baseline values at 24 h (47), and, conse-
quently, it is unlikely to have altered our 10 day samples
because they were taken at an average of five days after
heparin cessation.
Another potential limitation is the possible interference
by the catheterization and angioplasty procedures with the
natural evolution of thrombin generation and fibrinolytic
activity. Indeed, the higher need for catheterization or
angioplasty in the unstable group and the possible link
between these procedures and the activation of thrombin
formation (48,49) could have partly accounted for their
higher values. However, it was precisely to circumvent this
interference and that of the variable use of heparin during
the first days that the second samples were drawn at 10 days,
which is a time when most patients have already stabilized.
Although there are no studies analyzing the changes in the
parameters herein reported after catheterization, there ap-
pears to be a striking increase in C-reactive protein and
interleukin 6 after percutaneous transluminal coronary an-
gioplasty or coronary angiography, but only in UA patients
with high levels of C-reactive protein and interleukin 6
before the procedures and not in those with normal levels or
those with stable angina (49). These values, however, return
to baseline in 72 h (49). Among our patients only nine
(14%) had their angiography/percutaneous transluminal
coronary angioplasty performed between the 24 h to 72 h
before the 10th day sample, and five of them belong to the
stable subset. Moreover, since TAT and D-dimer have a
much shorter half-life than C-reactive protein, 5 min (38)
and 5 h to 8 h (28,39) versus 19 h (49), it seems improbable
that catheterization procedures could have significantly
influenced the changes observed in most of our patients.
Admittedly, the fact that our group of healthy controls
was younger than our patients subsets constitutes a limita-
tion. Thus, even though other groups have found similar
differences between patients and controls (14–16,21), it is
possible that the magnitude of our differences might not be
comparable with those of age-matched control studies.
Hence, our data need to be interpreted with caution.
Moreover, the relevance of our results with respect to the
incidence of infarction is very limited since the number of
patients studied is reduced. Nevertheless, there might be a
link with our findings because recurrence of angina appears
to be a good predictor of subsequent infarction (2–4,44,50).
Finally, we evaluated only symptomatic recurrent ischemia
and provided no information about silent ischemia. Thus,
theoretically, there is a possibility that, by analyzing asymp-
tomatic rather than symptomatic ischemia, the results could
have been different. However, silent ischemia is much more
likely to occur among patients with recurrent angina than it
would in those who remain asymptomatic (2,5,51).
Clinical implications. Our study extends previous obser-
vations on the persistence of a hypercoagulative state in
patients with UA or AMI. It adds, however, that this
becomes more apparent among patients with either UA or
AMI who remain unstable in the hospital. This subset,
moreover, already shows a particularly reduced fibrinolytic
capacity on admission. These findings, therefore, may shed
further light into the mechanisms of angina at rest in the
context of UA or AMI. They may suggest that the persis-
tence of a hypercoagulative condition may perhaps limit the
ability to reduce the size of the thrombi at the culprit lesion
and, hence, may facilitate additional deposition of fibrin or
platelet aggregates. The association with transient increases
in coronary tone, which seem to follow a circadian pattern
(8), would further reduce coronary flow leading to myocar-
dial ischemia. Our results, therefore, would be in concert
with the concept that a better control of thrombin genera-
tion, and possibly of platelet aggregation, will eventually
contribute to a better prevention of recurrent angina in at
least a number of these patients.
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